carbostyril has been researched along with Chronic Progressive Multiple Sclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barkhof, F; Cree, BAC; Giovannoni, G; Hartung, HP; Knappertz, V; Krieger, S; Li, T; Lublin, F; Montalban, X; Pia Sormani, M; Steinerman, JR; Tansy, AP; Uccelli, A; Uitdehaag, BMJ | 1 |
| Hainke, U; Thomas, K; Ziemssen, T | 1 |
1 review(s) available for carbostyril and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Laquinimod in the treatment of relapsing remitting multiple sclerosis.
Topics: Administration, Oral; Animals; Disease Models, Animal; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunologic Factors; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Neuritis, Autoimmune, Experimental; Quinolones | 2016 |
1 trial(s) available for carbostyril and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis.
Topics: Adult; Atrophy; Brain; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Quinolones; Spinal Cord; Treatment Outcome | 2020 |